Evidence map›Paper›PMID 41532405›Full record

ArticleeLife2026

Nonlinear transcriptional responses to gradual modulation of transcription factor dosage.

Júlia Domingo, Mariia Minaeva, John A Morris, Samuel Ghatan, Marcello Ziosi, Neville E Sanjana, Tuuli Lappalainen

Abstract read
In one paragraph

Article in eLife, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Targeting Microglial Transcriptional Reprogramming as a Therapy Strategy for Alzheimer's Disease.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Enhancer hubs govern chromatin topology and Th17 cell identity.bioRxiv : the preprint server for biology · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Júlia DomingoNew York Genome Center, New York, United States.ORCID https://orcid.org/0000-0001-6359-2785
Mariia MinaevaScience for Life Laboratory, Department of Gene Technology, KTH Royal Institute of Technology, Stockholm, Sweden.ORCID https://orcid.org/0000-0001-7028-1264
John A MorrisNew York Genome Center, New York, United States.ORCID https://orcid.org/0000-0003-2769-8202
Samuel GhatanNew York Genome Center, New York, United States.
Marcello ZiosiNew York Genome Center, New York, United States.
Neville E SanjanaNew York Genome Center, New York, United States.ORCID https://orcid.org/0000-0002-1504-0027
Tuuli LappalainenNew York Genome Center, New York, United States.ORCID https://orcid.org/0000-0002-7746-8109

Funding

Statistical models for fine-mapping and interpretation of schizophrenia-associated lociR01MH106842 · NIMH · NEW YORK GENOME CENTER · PI BUSSEMAKER, HARMEN J, LAPPALAINEN, TUULI · 2015 to 2024
$5.0M
UNDERSTANDING CELLULAR AND TRANSCRIPTIONAL REGULATORY CHANGES IN HUMAN AGINGR01AG057422 · NIA · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI GREALLY, JOHN, LAPPALAINEN, TUULI · 2018 to 2022
$4.5M
Multiscale genome engineering to map cis-regulatory variants in human and mouseR01HG012790 · NHGRI · NEW YORK GENOME CENTER · PI Tuuli Lappalainen, Dan Littman · 2023 to 2026
$4.5M
In situ functional genomics to understand transcriptional regulationDP2HG010099 · NHGRI · NEW YORK GENOME CENTER · PI SANJANA, NEVILLE · 2017 to 2022
$4.4M
Regulatory modifiers of coding variant penetrance via haplotype epistasis in human populations and diseasesR01GM122924 · NIGMS · NEW YORK GENOME CENTER · PI LAPPALAINEN, TUULI · 2017 to 2021
$1.7M
Linking GWAS variants to function with single-cell pooled CRISPR screensK99HG012792 · NHGRI · NEW YORK GENOME CENTER · PI MORRIS, JOHN ALLAN · 2023 to 2024
$123k
European Molecular Biology Organization ALTF 345-2021European Research Council 10.3030/101043238Knut and Alice Wallenberg Foundation KAW 2020.0239NHGRI NIH HHS DP2 HG010099NHGRI NIH HHS DP2HG010099NHGRI NIH HHS K99 HG012792NHGRI NIH HHS K99HG012792NHGRI NIH HHS R01 HG012790NHGRI NIH HHS R01HG012790NIA NIH HHS R01 AG057422NIA NIH HHS R01AG057422NIGMS NIH HHS R01 GM122924NIGMS NIH HHS R01GM122924NIMH NIH HHS R01 MH106842NIMH NIH HHS R01MH106842
6 · The paper itself

Abstract

Genomic loci associated with common traits and diseases are typically non-coding and likely impact gene expression, sometimes coinciding with rare loss-of-function variants in the target gene. However, our understanding of how gradual changes in gene dosage affect molecular, cellular, and organismal traits is currently limited. To address this gap, we induced gradual changes in gene expression of four genes using CRISPR activation and inactivation in human-derived K562 cells. Downstream transcriptional consequences of dosage modulation of three master trans-regulators associated with blood cell traits (

Indexed as

Gene DosageGene Expression RegulationTranscription FactorsTranscription, GeneticHumansK562 CellsSingle-Cell Gene Expression AnalysisTranscription Factorscomputational biologygene expressiongene regulationhumansystems biologytranscription factors

Identifiers

PMID41532405
PMCPMC12803512

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.